Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Aug;13(8):1321-1325.
doi: 10.1016/j.soard.2017.04.024. Epub 2017 Apr 26.

Long-term effects of bariatric surgery in patients with obesity and chromosome 16 p11.2 microdeletion

Felipe M Kristensson  1 , Johanna C Andersson-Assarsson  2 , Noora Kanerva  3 , Markku Peltonen  4 , Björn Carlsson  5 , Lena M S Carlsson  1
Affiliations
Clinical Trial

Long-term effects of bariatric surgery in patients with obesity and chromosome 16 p11.2 microdeletion

Felipe M Kristensson et al. Surg Obes Relat Dis. 2017 Aug.

Abstract

Background: Chromosome 16 p11.2 microdeletion is associated with early-onset obesity. Information is limited about the effect of bariatric surgery in patients with genetic obesity.

Objective: To examine the effects of bariatric surgery in obese patients with chromosome 16 p11.2 microdeletion.

Setting: Academic research institution.

Methods: The Swedish Obese Subjects study is a prospective study with 2010 participants receiving bariatric surgery. DNA was available for 1843 participants. Multiplex ligation-dependent probe amplification was used to identify 16 p11.2 microdeletion carriers. Follow-up time was 10 years. In carriers and noncarriers, follow-up rate was 86% and 82%, respectively, at 10 years.

Results: Nine carriers of the chromosome 16 p11.2 microdeletion (9/1843, .49%) were found. At baseline, most risk factors were similar; however, carriers had higher body mass index (BMI), insulin levels, and systolic blood pressure compared to noncarriers. At the 1-year examination, the percent excess BMI lost (%EBMIL) in carriers and noncarriers was 71.9 and 62.2, respectively; P = .031 (37.9 and 30.6 kg). This was followed by partial weight regain in both groups, and after 10 years %EBMIL was 25.5 and 41.5 (15.7 and 21.3 kg), respectively (P = .377). Changes in risk factors were similar in the carriers and noncarriers. Two carriers who had type 2 diabetes at baseline were both in remission at 2-year follow-up but relapsed at 10-year follow-up. Perceived health status was similar in carriers and noncarriers during follow-up (overall P = .198).

Conclusions: Despite a small sample size, our results indicate that bariatric surgery is a treatment option for obese patients with chromosome 16 p11.2 microdeletion.

Keywords: Bariatric surgery; Chromosome 16 p11.2 microdeletion; Obesity.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement

LMSC has obtained lecture fees from AstraZeneca, Johnson&Johnson and MSD. BC is employed by AstraZeneca and holds stocks in the same company. No other conflict of interest relevant to this study was reported.

Figures

Figure 1
Figure 1
Estimated means from mixed-models with 95% confidence intervals for body weight (a), body mass index (BMI) (b), energy intake (c) and perceived health status (d) in carriers and non-carriers of the 16p11.2 microdeletion followed for 10 years after bariatric surgery in the Swedish Obese Subjects (SOS) study. Orange dashed lines represent carriers of the 16p11.2 microdeletion, while solid blue lines represent non-carriers. b) Individual BMI trajectories for carriers of the 16p11.2 microdeletion are presented with narrow lines.
See this image and copyright information in PMC

Comment in

References

    1. Bray GA, Fruhbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet. 2016;387(10031):1947–56. - PubMed
    1. Abdeen G, le Roux CW. Mechanism Underlying the Weight Loss and Complications of Roux-en-Y Gastric Bypass. Review Obes Surg. 2016;26(2):410–21. - PMC - PubMed
    1. El-Sayed Moustafa JS, Froguel P. From obesity genetics to the future of personalized obesity therapy. Nature reviews Endocrinology. 2013;9(7):402–13. - PubMed
    1. Huvenne H, Dubern B, Clement K, Poitou C. Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016. Obes Facts. 2016;9(3):158–73. - PMC - PubMed
    1. Walters RG, Jacquemont S, Valsesia A, et al. A new highly penetrant form of obesity due to deletions on chromosome 16p11.2. Nature. 2010;463(7281):671–5. - PMC - PubMed

Publication types

MeSH terms